Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Involvement of Low-Density Lipoprotein Receptor in the Pathogenesis of Pulmonary Hypertension.

Umar S, Ruffenach G, Moazeni S, Vaillancourt M, Hong J, Cunningham C, Cao N, Navab S, Sarji S, Li M, Lee L, Fishbein G, Ardehali A, Navab M, Reddy ST, Eghbali M.

J Am Heart Assoc. 2020 Jan 21;9(2):e012063. doi: 10.1161/JAHA.119.012063. Epub 2020 Jan 9.

2.

Experimental Pulmonary Hypertension Is Associated With Neuroinflammation in the Spinal Cord.

Vaillancourt M, Chia P, Medzikovic L, Cao N, Ruffenach G, Younessi D, Umar S.

Front Physiol. 2019 Sep 20;10:1186. doi: 10.3389/fphys.2019.01186. eCollection 2019.

3.

Histological hallmarks and role of Slug/PIP axis in pulmonary hypertension secondary to pulmonary fibrosis.

Ruffenach G, Umar S, Vaillancourt M, Hong J, Cao N, Sarji S, Moazeni S, Cunningham CM, Ardehali A, Reddy ST, Saggar R, Fishbein G, Eghbali M.

EMBO Mol Med. 2019 Sep;11(9):e10061. doi: 10.15252/emmm.201810061. Epub 2019 Aug 29.

4.

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.

Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, BSc AB, Martel C, Vaillancourt M, Balser J, Moyneur É; members of the VVA Prasterone Research Group.

Menopause. 2018 Nov;25(11):1339-1353. doi: 10.1097/GME.0000000000001238.

PMID:
30358731
5.

In Reply.

Ke Y, Simard JN, Gonthier R, Martel C, Vaillancourt M, Portman D, Bélanger A, Labrie F.

Menopause. 2018 Aug;25(8):953-954. doi: 10.1097/GME.0000000000001147. No abstract available.

PMID:
29975286
6.

Free Fatty Acid Receptor G-protein-coupled Receptor 40 Mediates Lipid Emulsion-induced Cardioprotection.

Umar S, Li J, Hannabass K, Vaillancourt M, Cunningham CM, Moazeni S, Mahajan A, Eghbali M.

Anesthesiology. 2018 Jul;129(1):154-162. doi: 10.1097/ALN.0000000000002195. Erratum in: Anesthesiology. 2018 Jul;129(1):219.

7.

Concentration range of serum sex steroids in normal postmenopausal women and those with diagnosis of vulvovaginal atrophy.

Ke Y, Bélanger A, Simard JN, Gonthier R, Martel C, Vaillancourt M, Labrie F.

Menopause. 2018 Mar;25(3):293-300. doi: 10.1097/GME.0000000000000993.

PMID:
29206779
8.

Autonomic nervous system involvement in pulmonary arterial hypertension.

Vaillancourt M, Chia P, Sarji S, Nguyen J, Hoftman N, Ruffenach G, Eghbali M, Mahajan A, Umar S.

Respir Res. 2017 Dec 4;18(1):201. doi: 10.1186/s12931-017-0679-6. Review.

9.

The Y Chromosome Plays a Protective Role in Experimental Hypoxic Pulmonary Hypertension.

Umar S, Cunningham CM, Itoh Y, Moazeni S, Vaillancourt M, Sarji S, Centala A, Arnold AP, Eghbali M.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):952-955. doi: 10.1164/rccm.201707-1345LE. No abstract available.

10.

Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.

Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M.

Menopause. 2017 Nov;24(11):1246-1256. doi: 10.1097/GME.0000000000000910.

PMID:
28640161
11.

Double-Blind, Placebo-Controlled, Randomized Phase I/IIa Study (Safety and Efficacy) with Buspirone/Levodopa/Carbidopa (SpinalonTM) in Subjects with Complete AIS A or Motor-Complete AIS B Spinal Cord Injury.

Radhakrishna M, Steuer I, Prince F, Roberts M, Mongeon D, Kia M, Dyck S, Matte G, Vaillancourt M, Guertin PA.

Curr Pharm Des. 2017;23(12):1789-1804. doi: 10.2174/1381612822666161227152200.

PMID:
28025945
12.

Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.

Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN, Lavoie L, Vaillancourt M, Montesino M, Balser J, Moyneur É; other participating members of the Prasterone Clinical Research Group.

J Steroid Biochem Mol Biol. 2016 May;159:142-53. doi: 10.1016/j.jsbmb.2016.03.016. Epub 2016 Mar 10.

PMID:
26972555
13.

EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.

Jia Y, Juarez J, Li J, Manuia M, Niederst MJ, Tompkins C, Timple N, Vaillancourt MT, Pferdekamper AC, Lockerman EL, Li C, Anderson J, Costa C, Liao D, Murphy E, DiDonato M, Bursulaya B, Lelais G, Barretina J, McNeill M, Epple R, Marsilje TH, Pathan N, Engelman JA, Michellys PY, McNamara P, Harris J, Bender S, Kasibhatla S.

Cancer Res. 2016 Mar 15;76(6):1591-602. doi: 10.1158/0008-5472.CAN-15-2581. Epub 2016 Jan 29.

14.

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.

Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É; VVA Prasterone Research Group.

Menopause. 2016 Mar;23(3):243-56. doi: 10.1097/GME.0000000000000571.

PMID:
26731686
15.

Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.

Bouchard C, Labrie F, Derogatis L, Girard G, Ayotte N, Gallagher J, Cusan L, Archer DF, Portman D, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E; VVA Prasterone Group.

Horm Mol Biol Clin Investig. 2016 Mar;25(3):181-90. doi: 10.1515/hmbci-2015-0044.

16.

Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.

Montesino M, Labrie F, Archer DF, Zerhouni J, Côté I, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Moyneur E, Balser J.

Gynecol Endocrinol. 2016;32(3):240-5. doi: 10.3109/09513590.2015.1110140. Epub 2016 Jan 6.

PMID:
26634942
17.

Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.

Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É; Members of the VVA Prasterone Research Group.

J Sex Med. 2015 Dec;12(12):2401-12. doi: 10.1111/jsm.13045. Epub 2015 Nov 23.

PMID:
26597311
18.

Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.

Labrie F, Montesino M, Archer DF, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E; other participating Members of the Prasterone Clinical Research Group.

Climacteric. 2015;18(6):817-25. doi: 10.3109/13697137.2015.1077508. Epub 2015 Oct 30.

PMID:
26517756
19.

Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA.

Ke Y, Gonthier R, Simard JN, Archer D, Lavoie L, Martel C, Vaillancourt M, Labrie F.

Horm Mol Biol Clin Investig. 2015 Dec;24(3):117-29. doi: 10.1515/hmbci-2015-0035.

PMID:
26509785
20.

Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.

Ke Y, Labrie F, Gonthier R, Simard JN, Bergeron D, Martel C, Vaillancourt M, Montesino M, Lavoie L, Archer DF, Balser J, Moyneur E; other participating Members of the Prasterone Clinical Research Group.

J Steroid Biochem Mol Biol. 2015 Nov;154:186-96. doi: 10.1016/j.jsbmb.2015.08.016. Epub 2015 Aug 17.

PMID:
26291918
21.

Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension.

Meloche J, Potus F, Vaillancourt M, Bourgeois A, Johnson I, Deschamps L, Chabot S, Ruffenach G, Henry S, Breuils-Bonnet S, Tremblay È, Nadeau V, Lambert C, Paradis R, Provencher S, Bonnet S.

Circ Res. 2015 Aug 28;117(6):525-35. doi: 10.1161/CIRCRESAHA.115.307004. Epub 2015 Jul 29.

PMID:
26224795
22.

Exosome release following activation of the dendritic cell immunoreceptor: a potential role in HIV-1 pathogenesis.

Mfunyi CM, Vaillancourt M, Vitry J, Nsimba Batomene TR, Posvandzic A, Lambert AA, Gilbert C.

Virology. 2015 Oct;484:103-12. doi: 10.1016/j.virol.2015.05.013. Epub 2015 Jun 16.

23.

Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension.

Vaillancourt M, Ruffenach G, Meloche J, Bonnet S.

Can J Cardiol. 2015 Apr;31(4):407-15. doi: 10.1016/j.cjca.2014.10.023. Epub 2014 Oct 23. Review.

PMID:
25630876
24.

Acyclic tethers mimicking subunits of polysaccharide ligands: selectin antagonists.

Calosso M, Tambutet G, Charpentier D, St-Pierre G, Vaillancourt M, Bencheqroun M, Gratton JP, Prévost M, Guindon Y.

ACS Med Chem Lett. 2014 Jul 16;5(9):1054-9. doi: 10.1021/ml500266x. eCollection 2014 Sep 11.

25.

miRNAs in PAH: biomarker, therapeutic target or both?

Meloche J, Pflieger A, Vaillancourt M, Graydon C, Provencher S, Bonnet S.

Drug Discov Today. 2014 Aug;19(8):1264-9. doi: 10.1016/j.drudis.2014.05.015. Epub 2014 Jun 2. Review.

PMID:
24881781
26.

Role for DNA damage signaling in pulmonary arterial hypertension.

Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, Couture C, Michelakis ED, Provencher S, Bonnet S.

Circulation. 2014 Feb 18;129(7):786-97. doi: 10.1161/CIRCULATIONAHA.113.006167. Epub 2013 Nov 22.

PMID:
24270264
27.

Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.

Bissonnette S, Vaillancourt M, Hébert SS, Drolet G, Samadi P.

PLoS One. 2013 Sep 11;8(9):e75099. doi: 10.1371/journal.pone.0075099. eCollection 2013.

28.

Cross-linking of IgGs bound on circulating neutrophils leads to an activation of endothelial cells: possible role of rheumatoid factors in rheumatoid arthritis-associated vascular dysfunction.

Rollet-Labelle E, Vaillancourt M, Marois L, Newkirk MM, Poubelle PE, Naccache PH.

J Inflamm (Lond). 2013 Jul 31;10(1):27. doi: 10.1186/1476-9255-10-27.

30.

A new approach to explore the binding space of polysaccharide-based ligands: selectin antagonists.

Calosso M, Charpentier D, Vaillancourt M, Bencheqroun M, St-Pierre G, Wilkes BC, Guindon Y.

ACS Med Chem Lett. 2012 Oct 11;3(12):1045-9. doi: 10.1021/ml300263x. eCollection 2012 Dec 13.

31.

Mastery versus the standard proficiency target for basic laparoscopic skill training: effect on skill transfer and retention.

Kolozsvari NO, Kaneva P, Brace C, Chartrand G, Vaillancourt M, Cao J, Banaszek D, Demyttenaere S, Vassiliou MC, Fried GM, Feldman LS.

Surg Endosc. 2011 Jul;25(7):2063-70. doi: 10.1007/s00464-011-1743-9. Epub 2011 May 26.

PMID:
21614665
32.

CIN85 modulates the down-regulation of Fc gammaRIIa expression and function by c-Cbl in a PKC-dependent manner in human neutrophils.

Marois L, Vaillancourt M, Paré G, Gagné V, Fernandes MJ, Rollet-Labelle E, Naccache PH.

J Biol Chem. 2011 Apr 29;286(17):15073-84. doi: 10.1074/jbc.M110.213660. Epub 2011 Mar 3.

33.

Evaluation of surgical performance during laparoscopic incisional hernia repair: a multicenter study.

Ghaderi I, Vaillancourt M, Sroka G, Kaneva PA, Vassiliou MC, Choy I, Okrainec A, Seagull FJ, Sutton E, George I, Park A, Brintzenhoff R, Stefanidis D, Fried GM, Feldman LS.

Surg Endosc. 2011 Aug;25(8):2555-63. doi: 10.1007/s00464-011-1586-4. Epub 2011 Feb 27.

PMID:
21359893
34.

GOALS-incisional hernia: a valid assessment of simulated laparoscopic incisional hernia repair.

Vaillancourt M, Ghaderi I, Kaneva P, Vassiliou M, Kolozsvari N, George I, Sutton FE, Seagull FJ, Park AE, Fried GM, Feldman LS.

Surg Innov. 2011 Mar;18(1):48-54. doi: 10.1177/1553350610389826. Epub 2011 Jan 7.

PMID:
21216811
35.

Performance of simulated laparoscopic incisional hernia repair correlates with operating room performance.

Ghaderi I, Vaillancourt M, Sroka G, Kaneva PA, Seagull FJ, George I, Sutton E, Park AE, Vassiliou MC, Fried GM, Feldman LS.

Am J Surg. 2011 Jan;201(1):40-5. doi: 10.1016/j.amjsurg.2010.09.003.

PMID:
21167364
36.

Fc gammaRIIIb triggers raft-dependent calcium influx in IgG-mediated responses in human neutrophils.

Marois L, Paré G, Vaillancourt M, Rollet-Labelle E, Naccache PH.

J Biol Chem. 2011 Feb 4;286(5):3509-19. doi: 10.1074/jbc.M110.169516. Epub 2010 Dec 1.

37.

Determinants of masked hypertension in hypertensive patients treated in a primary care setting.

Andalib A, Akhtari S, Rigal R, Curnew G, Leclerc JM, Vaillancourt M, Tardif JC.

Intern Med J. 2012 Mar;42(3):260-6. doi: 10.1111/j.1445-5994.2010.02407.x.

PMID:
21118414
38.

Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study.

Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR; CADENCE Study Group (CAnadian Pilot Sutdy to Determine Safe and Effective Dosing of Neoral and CErtican in Stable Cardiac Transplant Recipients).

Transpl Int. 2010 Jan;23(1):31-7.

39.

Surgical Abdominal Wall (SAW): a novel simulator for training in ventral hernia repair.

Seagull FJ, George I, Ghaderi I, Vaillancourt M, Park A.

Surg Innov. 2009 Dec;16(4):330-6. doi: 10.1177/1553350609357057. Epub 2009 Dec 22.

PMID:
20031947
40.

The ubiquitin ligase c-Cbl down-regulates FcgammaRIIa activation in human neutrophils.

Marois L, Vaillancourt M, Marois S, Proulx S, Paré G, Rollet-Labelle E, Naccache PH.

J Immunol. 2009 Feb 15;182(4):2374-84. doi: 10.4049/jimmunol.0801420.

41.

Selective activation of apoptosis by a novel set of 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones through a Myc-dependent pathway.

Claassen G, Brin E, Crogan-Grundy C, Vaillancourt MT, Zhang HZ, Cai SX, Drewe J, Tseng B, Kasibhatla S.

Cancer Lett. 2009 Feb 18;274(2):243-9. doi: 10.1016/j.canlet.2008.09.032. Epub 2008 Nov 12.

PMID:
19008038
42.

Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.

Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR; CADENCE Study Group.

J Heart Lung Transplant. 2008 Feb;27(2):197-202. doi: 10.1016/j.healun.2007.11.565.

PMID:
18267227
43.

The Src homology 2-containing inositol 5-phosphatase 1 (SHIP1) is involved in CD32a signaling in human neutrophils.

Vaillancourt M, Levasseur S, Tremblay ML, Marois L, Rollet-Labelle E, Naccache PH.

Cell Signal. 2006 Nov;18(11):2022-32. Epub 2006 Apr 3.

PMID:
16682172
44.

Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implications for their use as oncolytic agents.

Vaillancourt MT, Atencio I, Quijano E, Howe JA, Ramachandra M.

Cancer Gene Ther. 2005 Aug;12(8):691-8.

PMID:
15877084
45.

[Psycho-behavioral function and attitude].

Vaillancourt M.

Soins Psychiatr. 2004 Nov-Dec;(235):20-4. French. No abstract available.

PMID:
15623255
46.

New real-time PCR assay for rapid detection of methicillin-resistant Staphylococcus aureus directly from specimens containing a mixture of staphylococci.

Huletsky A, Giroux R, Rossbach V, Gagnon M, Vaillancourt M, Bernier M, Gagnon F, Truchon K, Bastien M, Picard FJ, van Belkum A, Ouellette M, Roy PH, Bergeron MG.

J Clin Microbiol. 2004 May;42(5):1875-84.

47.

Restoration of transforming growth factor Beta signaling by functional expression of smad4 induces anoikis.

Ramachandra M, Atencio I, Rahman A, Vaillancourt M, Zou A, Avanzini J, Wills K, Bookstein R, Shabram P.

Cancer Res. 2002 Nov 1;62(21):6045-51.

48.

Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells.

Hirai M, LaFace D, Robinson S, Kelsey L, Johnson R, Wen SF, Warkentin P, Mills K, Vaillancourt M, Chavez J, Leutzinger C, Sumegi J, Neugebauer S, Lehman J, Talmadge C, Maneval D, Talmadge J.

Cancer Gene Ther. 2001 Dec;8(12):936-47.

49.

Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy.

Ramachandra M, Rahman A, Zou A, Vaillancourt M, Howe JA, Antelman D, Sugarman B, Demers GW, Engler H, Johnson D, Shabram P.

Nat Biotechnol. 2001 Nov;19(11):1035-41.

PMID:
11689848
50.

Intratumoral spread and increased efficacy of a p53-VP22 fusion protein expressed by a recombinant adenovirus.

Wills KN, Atencio IA, Avanzini JB, Neuteboom S, Phelan A, Philopena J, Sutjipto S, Vaillancourt MT, Wen SF, Ralston RO, Johnson DE.

J Virol. 2001 Sep;75(18):8733-41.

Supplemental Content

Loading ...
Support Center